Investors

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

NASDAQ: MRNS
$ 1.35 -0.10 (6.90%)
Day High: 1.44
Day Low:  1.32
Volume:    597,642
3:59 PM ET
Feb 22, 2017

Delayed ~20 min., by eSignal.